Group 1: Company Overview - The company introduced its basic situation, performance, and strategic plans for the chemical business segment based on the 2024 annual report and the 2025 Q1 report [2][3] - The company is focusing on the development of its AI segment, particularly in relation to its business strategy [3] Group 2: AI and Computing Power - The company chose Xinjiang for its AI layout due to its abundant green electricity resources and lower operational costs, despite concerns about latency for certain applications [4] - The company currently has nearly 4000P of high-end computing power and plans to expand based on customer orders and market conditions [10] - The company is actively exploring various value-added services to meet differentiated customer needs in the computing power sector [5] Group 3: Chemical Business Strategy - The main products are ACR and ACM, with ACM related to chlorine-alkali business; the company is implementing cost-reduction measures to improve profitability [7] - The company aims to enhance its product structure by reducing low-margin product orders and increasing high-margin products, while also expanding into overseas markets [7] - Long-term strategies include developing high-value new materials and creating a comprehensive industrial chain for ACR and ACM [7] Group 4: Market Challenges and Future Outlook - The company is facing significant market pressure in the short term but is optimistic about improving its operational status through strategic measures [7] - The company is closely monitoring the market for potential asset impairments and has already accounted for related losses [15] Group 5: Management and Organizational Changes - The company is undergoing systematic organizational adjustments to align with its new strategic direction, focusing on both chemical and AI sectors [15] - The first major shareholder holds 27.57% of the company, and the management team is committed to deepening its focus on the chemical industry [14]

As filed with the United States Securities and Exchange Commission on October 28, 2024. (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 13 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) Nevada 8071 87-2177170 (I.R.S. Employer Ide ...